SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License…
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc. a…
Read More...
Read More...
